Boston, MA, United States of America

Youssef Atoini

This inventor holds 1 USPTO granted patent. Top assignee: Riesner Verwaltungs Gmbh. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Youssef Atoini. Retrieved from https://idiyas.com/inventor/youssef-atoini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Youssef Atoini: Innovator in Medical Treatments

Introduction

Youssef Atoini is a notable inventor based in Boston, MA (US). He has made significant contributions to the field of medical treatments, particularly in the area of neurodegenerative diseases. His innovative work has led to the development of a patent that addresses critical health issues.

Latest Patents

Youssef Atoini holds a patent for "Polyvalent derivatives of emoxypine." This patent describes the use of polyvalent emoxypine derivatives or related compounds in the treatment or prevention of conditions such as Parkinson's Disease. His research focuses on enhancing the efficacy of these compounds to improve patient outcomes.

Career Highlights

Atoini is associated with Riesner Verwaltungs GmbH, where he continues to explore advancements in medical science. His dedication to research and innovation has positioned him as a key figure in the development of new therapeutic approaches.

Collaborations

Throughout his career, Atoini has collaborated with esteemed colleagues, including Renald Thinard and Claude Nicolau. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Youssef Atoini's contributions to medical innovation, particularly through his patent on emoxypine derivatives, highlight his commitment to improving healthcare solutions. His work continues to inspire advancements in the treatment of neurodegenerative diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…